Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV003169080 | SCV003856885 | likely pathogenic | Cardiovascular phenotype | 2023-01-20 | criteria provided, single submitter | clinical testing | The p.E14630* variant (also known as c.43888G>T), located in coding exon 153 of the TTN gene, results from a G to T substitution at nucleotide position 43888. This changes the amino acid from a glutamic acid to a stop codon within coding exon 153. This exon is located in the A-band region of the N2-B isoform of the titin protein and is constitutively expressed in TTN transcripts (percent spliced in or PSI 100%). This alteration has been reported in a cardiomyopathy/arrhythmia cohort; however, clinical details were limited (Kolokotronis K et al. J Clin Med, 2020 Jul;9:[ePub ahead of print]). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. While truncating variants in TTN are present in 1-3% of the general population, truncating variants in the A-band are the most common cause of dilated cardiomyopathy (DCM) (Herman DS et al. N. Engl. J. Med., 2012 Feb;366:619-28; Roberts AM et al. Sci Transl Med, 2015 Jan;7:270ra6). TTN truncating variants encoded in constitutive exons (PSI >90%) have been found to be significantly associated with DCM regardless of their position in titin (Schafer S et al. Nat. Genet., 2017 01;49:46-53). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Institute of Human Genetics, |
RCV000850280 | SCV000992455 | likely pathogenic | Primary dilated cardiomyopathy | no assertion criteria provided | clinical testing |